Header Logo

Connection

SAIRA KHADERI to Humans

Back to Details
This is a "connection" page, showing publications SAIRA KHADERI has written about Humans.
SAIRA KHADERI
Connection Strength
0.217
Humans
  1. Changing epidemiology of hepatocellular cancer in the United States: Winning the battle but it is not over yet. Hepatology. 2022 09; 76(3):546-548.
    View in: PubMed
    Score: 0.022
  2. Introduction: Alcohol and Alcoholism. Clin Liver Dis. 2019 02; 23(1):1-10.
    View in: PubMed
    Score: 0.018
  3. Project ECHO: The Specialist Will See You Now. Hepatology. 2018 12; 68(6):2066-2068.
    View in: PubMed
    Score: 0.017
  4. Is the Risk of Death Enhanced in Immunosuppressed Hepatitis B?Virus-infected Patients Who Develop Acute Liver Failure? Clin Gastroenterol Hepatol. 2017 01; 15(1):123-126.
    View in: PubMed
    Score: 0.015
  5. Screening for malignancy in primary sclerosing cholangitis (PSC). Curr Gastroenterol Rep. 2015 Apr; 17(4):17.
    View in: PubMed
    Score: 0.013
  6. Hepatitis C in the pediatric population: transmission, natural history, treatment and liver transplantation. World J Gastroenterol. 2014 Aug 28; 20(32):11281-6.
    View in: PubMed
    Score: 0.013
  7. Long-term follow-up of portopulmonary hypertension patients after liver transplantation. Liver Transpl. 2014 Jun; 20(6):724-7.
    View in: PubMed
    Score: 0.013
  8. Preventing a first episode of esophageal variceal hemorrhage. Cleve Clin J Med. 2008 Mar; 75(3):235-44.
    View in: PubMed
    Score: 0.008
  9. Phase 3 Validation of PAaM for Hepatocellular Carcinoma Risk Stratification in Cirrhosis. Gastroenterology. 2025 Mar; 168(3):556-567.e7.
    View in: PubMed
    Score: 0.007
  10. Serum levels of total bile acids are associated with an increased risk of HCC in patients with cirrhosis. Hepatol Commun. 2024 Nov 01; 8(11).
    View in: PubMed
    Score: 0.007
  11. HES V2.0 outperforms GALAD for detection of HCC: A phase 3 biomarker study in the United States. Hepatology. 2025 Feb 01; 81(2):465-475.
    View in: PubMed
    Score: 0.006
  12. PNPLA3, Obesity, and Heavy Alcohol Use in Cirrhosis Patients May Exert a Synergistic Increase Hepatocellular Carcinoma Risk. Clin Gastroenterol Hepatol. 2024 Sep; 22(9):1858-1866.e4.
    View in: PubMed
    Score: 0.006
  13. Genome-wide association study identifies high-impact susceptibility loci for HCC in North America. Hepatology. 2024 07 01; 80(1):87-101.
    View in: PubMed
    Score: 0.006
  14. Bioimpedance analysis predicts the etiology of cirrhosis in a prospective cohort study. Hepatol Commun. 2023 10 01; 7(10).
    View in: PubMed
    Score: 0.006
  15. Risk Stratification Model for Hepatocellular Cancer in Patients With Cirrhosis. Clin Gastroenterol Hepatol. 2023 12; 21(13):3296-3304.e3.
    View in: PubMed
    Score: 0.006
  16. Risk stratification for hepatocellular cancer among patients with cirrhosis using a hepatic fat polygenic risk score. PLoS One. 2023; 18(2):e0282309.
    View in: PubMed
    Score: 0.006
  17. Risk factors for HCC in contemporary cohorts of patients with cirrhosis. Hepatology. 2023 03 01; 77(3):997-1005.
    View in: PubMed
    Score: 0.006
  18. Cirrhosis Quality Collaborative. Clin Gastroenterol Hepatol. 2022 05; 20(5):970-972.
    View in: PubMed
    Score: 0.005
  19. A multidisciplinary approach to improving transition readiness in pediatric liver transplant recipients. Pediatr Transplant. 2021 03; 25(2):e13839.
    View in: PubMed
    Score: 0.005
  20. Risk Factors for Cirrhosis in Contemporary Hepatology Practices-Findings From the Texas Hepatocellular Carcinoma Consortium Cohort. Gastroenterology. 2020 07; 159(1):376-377.
    View in: PubMed
    Score: 0.005
  21. Design of the Texas Hepatocellular Carcinoma Consortium Cohort Study. Am J Gastroenterol. 2019 03; 114(3):530-532.
    View in: PubMed
    Score: 0.004
  22. Emricasan Improves Liver Function in Patients With Cirrhosis and High Model for End-Stage Liver Disease Scores Compared With Placebo. Clin Gastroenterol Hepatol. 2019 03; 17(4):774-783.e4.
    View in: PubMed
    Score: 0.004
  23. Cystatin C Is a Gender-Neutral Glomerular Filtration Rate Biomarker in Patients with Cirrhosis. Dig Dis Sci. 2018 03; 63(3):665-675.
    View in: PubMed
    Score: 0.004
  24. Estrogen Replacement Reduces Risk and Increases Survival Times of Women With Hepatocellular Carcinoma. Clin Gastroenterol Hepatol. 2017 Nov; 15(11):1791-1799.
    View in: PubMed
    Score: 0.004
  25. Is response guided therapy dead? Low cure rates in patients with detectable hepatitis C virus at week 4 of treatment. Hepatol Int. 2016 Jul; 10(4):624-31.
    View in: PubMed
    Score: 0.004
  26. Model for end-stage liver disease limbo, model for end-stage liver disease purgatory, and the dilemma of treating hepatitis C in patients awaiting liver transplantation. Liver Transpl. 2016 Mar; 22(3):279-80.
    View in: PubMed
    Score: 0.004
  27. Survival Outcomes Following Pediatric Liver Transplantation (Pedi-SOFT) Score: A Novel Predictive Index. Am J Transplant. 2015 Jul; 15(7):1855-63.
    View in: PubMed
    Score: 0.003
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.